Claims for Patent: 9,693,978

Summary for Patent: 9,693,978

Title:	Solvent system for enhancing the solubility of pharmaceutical agents
Abstract:	Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters.
Inventor(s):	Chidambaram; Nachiappan (Salt Lake City, UT), Fatmi; Aqeel (Greensboro, NC)
Assignee:	Banner Life Sciences LLC (High Point, NC)
Application Number:	14/977,808
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,693,978
Patent Claims:	1. A pharmaceutical composition comprising soft gelatin capsule comprising a fill material comprising: (a) a naproxen salt; (b) about 5% lactic acid by weight of the fill material; and (c) polyethylene glycol. 2. The composition of claim 1, wherein polyethylene glycol comprises about 10% to about 80% by weight of the fill material. 3. The composition of claim 1, wherein the polyethylene glycol comprises one or more polyethylene glycols comprising molecular weights between 300 and 1500. 4. The composition of claim 1, further comprising one or more excipients. 5. The composition of claim 4, wherein the excipients comprise plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, bioavailability enhancers, solvents, pH-adjusting agents, dyes, preservatives, solvents, surfactants, or combinations thereof. 6. The composition of claim 1, further comprising a solubilizer selected from glycerin, polyvinylpyrrolidone, propylene glycol, or a combination thereof. 7. The composition of claim 6, wherein the solubilizer is present in amount from about 1% to about 10% by weight of the fill material. 8. A method of making the composition of claim 1, the method comprising the steps of: (i) mixing the naproxen salt, lactic acid, and polyethylene glycol at an appropriate temperature to form a fill material; and (ii) encapsulating the fill material in a soft gelatin capsule. 9. The method of claim 8, wherein the appropriate temperature is from about 50.degree. C. to about 70.degree. C. 10. A soft gelatin capsule comprising a fill material, the fill material comprising: (a) a naproxen salt; (b) about 5% lactic acid by weight of the fill material; and (c) polyethylene glycol. 11. The capsule of claim 10, wherein polyethylene glycol comprises about 10% to about 80% by weight of the fill material. 12. The capsule of claim 10, wherein the polyethylene glycol comprises one or more polyethylene glycols comprising molecular weights between 300 and 1500. 13. The capsule of claim 10, further comprising one or more excipients. 14. The capsule of claim 13, wherein the excipients comprise plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, bioavailability enhancers, solvents, pH-adjusting agents, dyes, preservatives, solvents, surfactants, or combinations thereof. 15. The capsule of claim 10, further comprising a solubilizer selected from glycerin, polyvinylpyrrolidone, propylene glycol or a combination thereof. 16. The capsule of claim 15, wherein the solubilizer comprises about 1% to about 10% by weight of the fill material. 17. A method of using the capsule of claim 10 comprising administering to a patient in need thereof an effective amount of the capsule. 18. A soft gelatin capsule comprising a fill material comprising: (a) about 10% to about 80% by weight of the fill material polyethylene glycol having a molecular weight between 300 and 1500; (b) about 10% to about 50% by weight of the fill material naproxen sodium; and (c) about 5% of the fill material lactic acid. 19. A method of using the capsule of claim 18 comprising administering to a patient in need thereof an effective amount of the capsule. 20. A pharmaceutical composition prepared by a method comprising preparing a fill material comprising: mixing together (a) a naproxen salt; (b) about 5% by weight of the fill material lactic acid; and (c) polyethylene glycol having a molecular weight between 300 and 1500. 21. A soft gelatin capsule prepared by a method comprising: (a) producing a fill material by mixing: (i) a naproxen salt; (ii) about 5% by weight of the fill material lactic acid; (iii) polyethylene glycol having a molecular weight between 300 and 1500; and (b) encapsulating the mixture in a soft gelatin capsule. 22. The composition of claim 1, wherein the naproxen salt comprises sodium naproxen. 23. The composition of claim 6, wherein the solubilizer comprises polyvinylpyrrolidone. 24. The method of claim 8, wherein the naproxen salt comprises sodium naproxen. 25. A capsule produced by the method of claim 8. 26. The capsule of claim 10, wherein the naproxen salt comprises sodium naproxen. 27. The capsule of claim 15, wherein the solubilizer comprises polyvinylpyrrolidone. 28. The capsule of claim 18, wherein the fill further comprises a solubilizer. 29. The capsule of claim 28, wherein the solubilizer comprises about 1% to about 10% by weight of the fill material. 30. The capsule of claim 28, wherein the solubilizer comprises polyvinylpyrrolidone. 31. The method of claim 20, wherein the naproxen salt comprises sodium naproxen. 32. The method of claim 20, wherein the fill material further comprises a solubilizer. 33. The method of claim 32, wherein the solubilizer comprises about 1% to about 10% by weight of the fill material. 34. The method of claim 32, wherein the solubilizer comprises polyvinylpyrrolidone. 35. The capsule of claim 21, wherein the naproxen salt comprises sodium naproxen. 36. The capsule of claim 21, wherein the fill material further comprises a solubilizer. 37. The capsule of claim 36, wherein the solubilizer comprises about 1% to about 10% by weight of the fill material. 38. The capsule of claim 36, wherein the solubilizer comprises polyvinylpyrrolidone.